InDex Pharmaceuticals Holding AB (INDEX):企業の財務・戦略的SWOT分析

◆英語タイトル:InDex Pharmaceuticals Holding AB (INDEX) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH93499FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥66,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥99,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
InDex Pharmaceuticals Holding AB (InDex Pharmaceuticals) is a pharmaceutical company that offers treatments for immunological diseases. The company’s lead compound cobitolimod, currently in the phase 2 stage, is intended for the treatment of moderate to severe treatment active refractory ulcerative colitis. Its preclinical products include DIMS 9054, and DIMS 9059, which are intended for treating resistant pulmonary inflammation and cancer. InDex Pharmaceuticals offers dibicol, a PCR-based method that monitors proprietary biomarkers used for ulcerative colitis. The company conducts clinical studies in the Czech Republic, France, Germany, Hungary, Spain, Russia, Italy, Poland, Romania, Serbia, Sweden, and Ukraine. InDex Pharmaceuticals is headquartered in Stockholm, Sweden.

InDex Pharmaceuticals Holding AB Key Recent Developments

Apr 07,2021: InDex Pharmaceuticals gets patent for additional DIMS compounds granted in Europe
Mar 30,2021: InDex Pharmaceuticals enters agreement with Parexel Biotech for phase III clinical study of cobitolimod for ulcerative colitis
Mar 10,2021: InDex Pharmaceuticals presents at Barclays Global Healthcare Conference and Carnegie Nordic Virtual Healthcare Seminar
Nov 25,2020: InDex Pharmaceuticals Holding: interim report January – September 2020
Aug 26,2020: InDex Pharmaceuticals Holding : Interim report January – June 2020

This comprehensive SWOT profile of InDex Pharmaceuticals Holding AB provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of InDex Pharmaceuticals Holding AB including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

InDex Pharmaceuticals Holding AB – Key Information
InDex Pharmaceuticals Holding AB – Overview
InDex Pharmaceuticals Holding AB – Key Employees
InDex Pharmaceuticals Holding AB – Key Employee Biographies
InDex Pharmaceuticals Holding AB – Key Operational Heads
InDex Pharmaceuticals Holding AB – Major Products and Services
InDex Pharmaceuticals Holding AB – History
InDex Pharmaceuticals Holding AB – Company Statement
InDex Pharmaceuticals Holding AB – Locations And Subsidiaries
InDex Pharmaceuticals Holding AB
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

InDex Pharmaceuticals Holding AB – Business Description
InDex Pharmaceuticals Holding AB – Corporate Strategy
InDex Pharmaceuticals Holding AB – SWOT Analysis
SWOT Analysis – Overview
InDex Pharmaceuticals Holding AB – Strengths
InDex Pharmaceuticals Holding AB – Weaknesses
InDex Pharmaceuticals Holding AB – Opportunities
InDex Pharmaceuticals Holding AB – Threats
InDex Pharmaceuticals Holding AB – Key Competitors

Section 3 – Company Financial Performance Charts

InDex Pharmaceuticals Holding AB – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

InDex Pharmaceuticals Holding AB, Key Information
InDex Pharmaceuticals Holding AB, Key Ratios
InDex Pharmaceuticals Holding AB, Share Data
InDex Pharmaceuticals Holding AB, Major Products and Services
InDex Pharmaceuticals Holding AB, History
InDex Pharmaceuticals Holding AB, Key Employees
InDex Pharmaceuticals Holding AB, Key Employee Biographies
InDex Pharmaceuticals Holding AB, Key Operational Heads
InDex Pharmaceuticals Holding AB, Other Locations
InDex Pharmaceuticals Holding AB, Subsidiaries
InDex Pharmaceuticals Holding AB, Key Competitors
InDex Pharmaceuticals Holding AB, SWOT Analysis
InDex Pharmaceuticals Holding AB, Ratios based on current share price
InDex Pharmaceuticals Holding AB, Annual Ratios
InDex Pharmaceuticals Holding AB, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[InDex Pharmaceuticals Holding AB (INDEX):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • MPC Munchmeyer Petersen Capital AG (MPCK):企業の財務・戦略的SWOT分析
    Summary MPC Munchmeyer Petersen Capital AG (MPC), a subsidiary of MPC Munchmeyer Petersen & Co GmbH, is an asset and investment management firm. The firm business segments include infrastructure, real estate and shipping. Its real estate business concentrates on micro living or student housing. Its …
  • Intrado Corp:企業の戦略的SWOT分析
    Intrado Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Canam Group Inc:企業の戦略的SWOT分析
    Canam Group Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Daisy IT Group Ltd:企業の戦略的SWOT分析
    Daisy IT Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Tocagen Inc (TOCA):製薬・医療:M&Aディール及び事業提携情報
    Summary Tocagen Inc (Tocagen) is a clinical-stage cancer-selective gene therapy company that develops and commercializes product candidates for the treatment of cancer. The company offers lead product candidate such as Toca 511 and Toca FC, which is being investigated for the treatment of recurrent …
  • Royal BAM Group nv:企業の戦略・SWOT・財務分析
    Royal BAM Group nv - Strategy, SWOT and Corporate Finance Report Summary Royal BAM Group nv - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Toro Energy Limited (TOE):企業の財務・戦略的SWOT分析
    Toro Energy Limited (TOE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • The Yomiuri Shimbun:企業の戦略的SWOT分析
    The Yomiuri Shimbun - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Tandem Diabetes Care Inc (TNDM):企業の財務・戦略的SWOT分析
    Summary Tandem Diabetes Care Inc (Tandem) is a medical device manufacturing company that designs and develops diabetic care products. The company's product portfolio includes t:slim X2 insulin pump, basal-IQ technology, software and applications, infusion sets and other pump accessories. It also pro …
  • Fair Isaac Corp (FICO):企業の財務・戦略的SWOT分析
    Fair Isaac Corp (FICO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Medinet Co Ltd (2370):製薬・医療:M&Aディール及び事業提携情報
    Summary Medinet Co Ltd (Medinet) is a regenerative medicine and cell therapy products developer. The company manufactures regenerative medical products and investigational products, and specified cell products. It provides somatic cell, somatic stem cell and induced pluripotent stem cell. Medinet pr …
  • eResearchTechnology Inc:企業の戦略的SWOT分析
    eResearchTechnology Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Healthscope Ltd:企業の戦略的SWOT分析
    Healthscope Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Rolls-Royce Holdings Plc:企業のM&A・事業提携・投資動向
    Rolls-Royce Holdings Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Rolls-Royce Holdings Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Natrix Separations Inc-製薬・医療分野:企業M&A・提携分析
    Summary Natrix Separations Inc (Natrix), formerly Nysa Membrane Technologies is a medical device company that provides disposable products. The company’s products line comprise HD-Q membrane adsorbers and bind-elute products. Its HD-Q membrane adsorbers finds application in single-use flow-through p …
  • Teijin Limited:戦略・SWOT・企業財務分析
    Teijin Limited - Strategy, SWOT and Corporate Finance Report Summary Teijin Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • United Networks Ltd (UNL):企業の財務・戦略的SWOT分析
    United Networks Ltd (UNL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • RayBiotech Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary RayBiotech Inc (RayBiotech) is a life science company that provides proteins, antibodies and immunological kits. The company's product categories include antibody arrays, glycobiology arrays, protein arrays, phosphorylation arrays, elisa, functional assays, antibodies and custom recombinant …
  • Entegris Inc (ENTG):企業の財務・戦略的SWOT分析
    Summary Entegris Inc (Entegris) is a manufacturer and supplier of micro contamination control products, specialty chemicals, and advanced materials handling solutions. The company offers products for wafer shipping and processing; gas filtration and purification; mask and reticle handling; hard disk …
  • Forma Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Forma Therapeutics Inc (Forma) is a drug discovery and development company that discovers and develops new transformative cancer therapeutics. The company develops technologies to identify the initial molecules that provide drug discovery program. It offers research in the areas of tumor met …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆